Adagio medical unveils preliminary acute results from fulcrum-vt u.s. pivotal study in late breaking session at vt symposium

Laguna hills, calif.--(business wire)--adagio medical holdings, inc. (nasdaq: adgm) (“adagio” or “the company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced preliminary acute (within 7 days) safety and efficacy results from the adagio's fulcrum-vt study evaluating ultralow temperature cryoablation (“ultc”) for the treatment of sustained monomorphic ventricular tachycardia (“smvt”) in patients with both ischemic and nonischemic.
ADGM Ratings Summary
ADGM Quant Ranking